Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Arun Azad
- , Craig R. Underhill
- , Howard Gurney
- , Lisa Horvath
- , Mark Voskoboynik
- , Scott Ellerington
- , Yiyun Dai
- , Ivan King
- , Frank Perabo
- , George Guo
Research output: Contribution to journal › Meeting abstract › peer-review
2
Link opens in a new tab
Citations
(Scopus)